TaiRx

TaiRx EPS

The Earnings per Share (EPS) of TaiRx (6580.TWO) as of Oct 15, 2026 is -2.00 TWD. In the previous year, Earnings per Share (EPS) was -1.26 TWD — a change of 59.16% (lower).

EPS

-2.00TWD

YoY

59.16%

Last updated:

Earnings per Share (EPS) of TaiRx is 2025 -2.00 TWD. Earnings per Share (EPS) of TaiRx was 2024 -1.26 TWD. It decreases by 59.16% lower compared to the previous year.

The TaiRx EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
-3.36 TWD
Jan 1, 2019
-3.60 TWD
Jan 1, 2020
-2.37 TWD
Jan 1, 2021
-1.38 TWD
Jan 1, 2022
-2.37 TWD
Jan 1, 2023
-2.26 TWD
Jan 1, 2024
-1.26 TWD
Jan 1, 2025
-2.00 TWD
The TaiRx EPS history
YEAREPSYoY
-2.00TWD+59.16%
-1.26TWD-44.40%
-2.26TWD-4.59%
-2.37TWD+71.24%
-1.38TWD-41.64%
-2.37TWD-34.21%
-3.60TWD+6.97%
-3.36TWD+60.49%
-2.10TWD+6.97%
-1.96TWD+18.47%
-1.65TWD-36.09%
-2.59TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TaiRx Stock analysis

What does TaiRx do? TaiRx Inc, listed on the Taiwan Stock Exchange under ticker 6580.TWO with ISIN TW0006580004, is a biotechnology company based in Taipei City, Taiwan. The company operates within the Health Care sector, focusing on research and development of novel drug products for cancer treatment. TaiRx went public through an IPO on June 20, 2017. Its primary focus includes the development of cancer treatment drugs and sepsis adjuvant therapy drugs. The company's product portfolio includes CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, and TRX-105. Among these, CVM-1118 and Rexis are currently in clinical trials. Zelnite is distributed to domestic medical institutions at all levels through distributors. TaiRx maintains a corporate website at https://www.trx.com.tw/, where further information about its operations and products can be found. The company is engaged in the research and development of innovative pharmaceutical solutions, targeting significant unmet medical needs in oncology and sepsis treatment. TaiRx's activities are centered on advancing drug candidates through clinical development and commercialization within the Taiwanese market and potentially beyond. The company's operations are conducted from its headquarters in Taipei City, reflecting its commitment to contributing to the healthcare industry in Taiwan and globally. TaiRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TaiRx stock

Earnings per Share (EPS) of TaiRx is -2.00 TWD in 2025.

Earnings per Share (EPS) of TaiRx changed from -1.26 TWD to -2.00 TWD, representing a 59.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) TaiRx since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — TaiRx

All Key Metrics — TaiRx